Suppr超能文献

精神分裂症和双相情感障碍患者未满足的抗精神病治疗需求:来自定性焦点小组的患者观点。

Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups.

机构信息

Alkermes, Inc., Waltham, MA, USA.

QualityMetric, Inc. LLC, Johnston, RI, USA.

出版信息

BMC Psychiatry. 2023 Apr 12;23(1):245. doi: 10.1186/s12888-023-04746-4.

Abstract

BACKGROUND

Schizophrenia (SZ) and bipolar I disorder (BD-I) are chronic mental health disorders often treated with antipsychotic medications. This qualitative study sought to better understand disease burden and treatment experiences with oral antipsychotic medications in participants living with SZ or BD-I.

METHODS

Six 90-min focus groups were conducted with participants diagnosed with SZ or BD-I. Trained moderators facilitated discussions using a semistructured guide. Participants described symptoms, impacts of disease, and experiences with oral antipsychotic medications, whether favourable or unfavourable.

RESULTS

Among participants with SZ (n = 15; 3 groups, 5 per group), 53% were male and 33% were white, with a mean of 18.6 years since diagnosis. Of participants with BD-I (n = 24; 3 groups, 8 per group), 33% were male and 42% were white, with a mean of 13.0 years since diagnosis. Participants described numerous symptoms of their illnesses that impacted relationships and daily life, including effects on emotional health, the ability to work, and encounters with law enforcement. Previous antipsychotic medications were deemed effective by 14/15 (93%) participants with SZ and 12/16 (75%) participants with BD-I. Most participants with SZ (13/15; 87%) or with BD-I (16/24; 67%) reported discontinuing their antipsychotic medication at some point. Side effects were a common reason for discontinuing or switching medications for participants with SZ (8/15; 53%) and for those with BD-I (11/24; 46%). The most common side effects reported in both cohorts were weight gain, drowsiness, sexual problems, and neurologic symptoms. Side effects negatively affected quality of life, leading to serious health problems and issues with self-esteem.

CONCLUSIONS

People living with SZ or BD-I cited a range of favourable and unfavourable experiences with oral antipsychotic medications. Most participants reported that their antipsychotics were effective at controlling their symptoms, but multiple side effects impacted their quality of life, caused additional serious health problems, and often led to discontinuation of or switching antipsychotics. Findings from this study contribute to a better understanding of patients' experiences with antipsychotics and highlight a need for new medications with favourable benefit/risk profiles.

摘要

背景

精神分裂症(SZ)和双相情感障碍 I 型(BD-I)是常见的慢性精神健康障碍,通常采用抗精神病药物治疗。本定性研究旨在深入了解 SZ 或 BD-I 患者使用口服抗精神病药物的疾病负担和治疗体验。

方法

对 15 名 SZ 患者(3 组,每组 5 人)和 24 名 BD-I 患者(3 组,每组 8 人)进行了 6 次 90 分钟的焦点小组讨论。培训有素的主持人使用半结构式指南促进讨论。参与者描述了症状、疾病的影响以及对口服抗精神病药物的治疗体验,无论好坏。

结果

在 SZ 患者中(n=15;3 组,每组 5 人),53%为男性,33%为白人,诊断后平均 18.6 年。BD-I 患者中(n=24;3 组,每组 8 人),33%为男性,42%为白人,诊断后平均 13.0 年。参与者描述了他们疾病的许多症状,这些症状影响了人际关系和日常生活,包括对情绪健康、工作能力和与执法部门的接触的影响。14/15(93%)名 SZ 患者和 12/16(75%)名 BD-I 患者认为之前的抗精神病药物有效。大多数 SZ 患者(13/15;87%)或 BD-I 患者(16/24;67%)报告在某个时候停止服用抗精神病药物。对于 SZ 患者(8/15;53%)和 BD-I 患者(11/24;46%)来说,副作用是停止或更换药物的常见原因。在这两个队列中报告的最常见副作用是体重增加、嗜睡、性问题和神经症状。副作用对生活质量产生负面影响,导致严重的健康问题和自尊心问题。

结论

SZ 或 BD-I 患者对口服抗精神病药物有一系列有利和不利的治疗体验。大多数参与者报告说,他们的抗精神病药物能有效控制症状,但多种副作用影响了他们的生活质量,导致了更多严重的健康问题,往往导致抗精神病药物的停药或换药。本研究的结果有助于更好地了解患者对抗精神病药物的治疗体验,并强调需要具有良好获益/风险特征的新药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1a5/10091535/65e705544409/12888_2023_4746_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验